2,025 research outputs found

    Multimodal MRI-based Imputation of the Aβ+ in Early Mild Cognitive Impairment.

    Get PDF
    ObjectiveTo identify brain atrophy from structural-MRI and cerebral blood flow(CBF) patterns from arterial spin labeling perfusion-MRI that are best predictors of the Aβ-burden, measured as composite 18F-AV45-PET uptake, in individuals with early mild cognitive impairment(MCI). Furthermore, to assess the relative importance of imaging modalities in classification of Aβ+/Aβ- early mild cognitive impairment.MethodsSixty-seven ADNI-GO/2 participants with early-MCI were included. Voxel-wise anatomical shape variation measures were computed by estimating the initial diffeomorphic mapping momenta from an unbiased control template. CBF measures normalized to average motor cortex CBF were mapped onto the template space. Using partial least squares regression, we identified the structural and CBF signatures of Aβ after accounting for normal cofounding effects of age, sex, and education.Results18F-AV45-positive early-MCIs could be identified with 83% classification accuracy, 87% positive predictive value, and 84% negative predictive value by multidisciplinary classifiers combining demographics data, ApoE ε4-genotype, and a multimodal MRI-based Aβ score.InterpretationMultimodal-MRI can be used to predict the amyloid status of early-MCI individuals. MRI is a very attractive candidate for the identification of inexpensive and non-invasive surrogate biomarkers of Aβ deposition. Our approach is expected to have value for the identification of individuals likely to be Aβ+ in circumstances where cost or logistical problems prevent Aβ detection using cerebrospinal fluid analysis or Aβ-PET. This can also be used in clinical settings and clinical trials, aiding subject recruitment and evaluation of treatment efficacy. Imputation of the Aβ-positivity status could also complement Aβ-PET by identifying individuals who would benefit the most from this assessment

    Ultra-deep Large Binocular Camera U-band Imaging of the GOODS-North Field: Depth vs. Resolution

    Get PDF
    We present a study of the trade-off between depth and resolution using a large number of U-band imaging observations in the GOODS-North field (Giavalisco et al. 2004) from the Large Binocular Camera (LBC) on the Large Binocular Telescope (LBT). Having acquired over 30 hours of data (315 images with 5-6 mins exposures), we generated multiple image mosaics, starting with the best atmospheric seeing images (FWHM \lesssim0.8"), which constitute \sim10% of the total data set. For subsequent mosaics, we added in data with larger seeing values until the final, deepest mosaic included all images with FWHM \lesssim1.8" (\sim94% of the total data set). From the mosaics, we made object catalogs to compare the optimal-resolution, yet shallower image to the lower-resolution but deeper image. We show that the number counts for both images are \sim90% complete to UABU_{AB} 26\lesssim26. Fainter than UABU_{AB}\sim 27, the object counts from the optimal-resolution image start to drop-off dramatically (90% between UABU_{AB} = 27 and 28 mag), while the deepest image with better surface-brightness sensitivity (μUAB\mu^{AB}_{U}\lesssim 32 mag arcsec2^{-2}) show a more gradual drop (10% between UABU_{AB} \simeq 27 and 28 mag). For the brightest galaxies within the GOODS-N field, structure and clumpy features within the galaxies are more prominent in the optimal-resolution image compared to the deeper mosaics. Finally, we find - for 220 brighter galaxies with UABU_{AB}\lesssim 24 mag - only marginal differences in total flux between the optimal-resolution and lower-resolution light-profiles to μUAB\mu^{AB}_{U}\lesssim 32 mag arcsec2^{-2}. In only 10% of the cases are the total-flux differences larger than 0.5 mag. This helps constrain how much flux can be missed from galaxy outskirts, which is important for studies of the Extragalactic Background Light.Comment: 24 pages, 14 figures, submitted to PASP, comments welcom

    The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI)

    Get PDF
    Objective: Our goal was to evaluate the association of APOE with amyloid deposition, cerebrospinal fluid levels (CSF) of Aβ, tau, and p-tau, brain atrophy, cognition and cognitive complaints in E-MCI patients and cognitively healthy older adults (HC) in the ADNI-2 cohort. Methods: Two-hundred and nine E-MCI and 123 HC participants from the ADNI-2 cohort were included. We evaluated the impact of diagnostic status (E-MCI vs. HC) and APOE ε4 status (ε4 positive vs. ε4 negative) on cortical amyloid deposition (AV-45/Florbetapir SUVR PET scans), brain atrophy (structural MRI scans processed using voxel-based morphometry and Freesurfer version 5.1), CSF levels of Aβ, tau, and p-tau, and cognitive performance and complaints. Results: E-MCI participants showed significantly impaired cognition, higher levels of cognitive complaints, greater levels of tau and p-tau, and subcortical and cortical atrophy relative to HC participants (p < 0.05). Cortical amyloid deposition and CSF levels of Aβ were significantly associated with APOE ε4 status but not E-MCI diagnosis, with ε4 positive participants showing more amyloid deposition and lower levels of CSF Aβ than ε4 negative participants. Other effects of APOE ε4 status on cognition and CSF tau levels were also observed. Conclusions: APOE ε4 status is associated with amyloid accumulation and lower CSF Aβ, as well as increased CSF tau levels in early prodromal stages of AD (E-MCI) and HC. Alternatively, neurodegeneration, cognitive impairment, and increased complaints are primarily associated with a diagnosis of E-MCI. These findings underscore the importance of considering APOE genotype when evaluating biomarkers in early stages of disease

    Reflecting on loss in Papua New Guinea

    Get PDF
    This article takes up the conundrum of conducting anthropological fieldwork with people who claim that they have 'lost their culture,' as is the case with Suau people in the Massim region of Papua New Guinea. But rather than claiming culture loss as a process of dispossession, Suau claim it as a consequence of their own attempts to engage with colonial interests. Suau appear to have responded to missionization and their close proximity to the colonial-era capital by jettisoning many of the practices characteristic of Massim societies, now identified as 'kastom.' The rejection of kastom in order to facilitate their relations with Europeans during colonialism, followed by the mourning for kastom after independence, both invite consideration of a kind of reflexivity that requires action based on the presumed perspective of another

    The Apache Point Observatory Galactic Evolution Experiment: First Detection of High Velocity Milky Way Bar Stars

    Full text link
    Commissioning observations with the Apache Point Observatory Galactic Evolution Experiment (APOGEE), part of the Sloan Digital Sky Survey III, have produced radial velocities (RVs) for ~4700 K/M-giant stars in the Milky Way bulge. These high-resolution (R \sim 22,500), high-S/N (>100 per resolution element), near-infrared (1.51-1.70 um; NIR) spectra provide accurate RVs (epsilon_v~0.2 km/s) for the sample of stars in 18 Galactic bulge fields spanning -1-32 deg. This represents the largest NIR high-resolution spectroscopic sample of giant stars ever assembled in this region of the Galaxy. A cold (sigma_v~30 km/s), high-velocity peak (V_GSR \sim +200 km/s) is found to comprise a significant fraction (~10%) of stars in many of these fields. These high RVs have not been detected in previous MW surveys and are not expected for a simple, circularly rotating disk. Preliminary distance estimates rule out an origin from the background Sagittarius tidal stream or a new stream in the MW disk. Comparison to various Galactic models suggests that these high RVs are best explained by stars in orbits of the Galactic bar potential, although some observational features remain unexplained.Comment: 7 pages, 4 figures, accepted for publication in ApJ Letter

    Whole Genome Pyrosequencing of Rare Hepatitis C Virus Genotypes Enhances Subtype Classification and Identification of Naturally Occurring Drug Resistance Variants

    Get PDF
    Background. Infection with hepatitis C virus (HCV) is a burgeoning worldwide public health problem, with 170 million infected individuals and an estimated 20 million deaths in the coming decades. While 6 main genotypes generally distinguish the global geographic diversity of HCV, a multitude of closely related subtypes within these genotypes are poorly defined and may influence clinical outcome and treatment options. Unfortunately, the paucity of genetic data from many of these subtypes makes time-consuming primer walking the limiting step for sequencing understudied subtypes. Methods. Here we combined long-range polymerase chain reaction amplification with pyrosequencing for a rapid approach to generate the complete viral coding region of 31 samples representing poorly defined HCV subtypes. Results. Phylogenetic classification based on full genome sequences validated previously identified HCV subtypes, identified a recombinant sequence, and identified a new distinct subtype of genotype 4. Unlike conventional sequencing methods, use of deep sequencing also facilitated characterization of minor drug resistance variants within these uncommon or, in some cases, previously uncharacterized HCV subtypes. Conclusions. These data aid in the classification of uncommon HCV subtypes while also providing a high-resolution view of viral diversity within infected patients, which may be relevant to the development of therapeutic regimens to minimize drug resistanc

    Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

    Get PDF
    INTRODUCTION: The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. METHODS: We searched for ADNI publications using established methods. RESULTS: ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. DISCUSSION: ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials
    corecore